安罗替尼联合TC化疗方案治疗驱动基因阴性晚期肺腺癌的临床效果

Clinical effect of anlotinib combined with TC chemotherapy regimen in the treatment of advanced lung adenocarcinoma with negative driver gene

目的分析安罗替尼联合TC化疗方案治疗驱动基因阴性晚期肺腺癌的临床效果及对血清肿瘤标志物与卡氏功能量表(KPS)评分的影响。方法回顾性选取2019年8月—2020年11月衡阳市中心医院收治的驱动基因阴性晚期肺腺癌患者80例,根据治疗方案不同分为观察组和对照组各40例。对照组采用TC化疗方案,观察组在对照组治疗基础上加用盐酸安罗替尼胶囊治疗,比较2组疾病控制率,治疗前后血清肿瘤标志物[神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)、糖类抗原125(CA125)]水平、KPS评分、肺癌治疗功能性量表(FACT-L)评分,以及不良反应发生情况。结果观察组疾病控制率为95.00%,高于对照组的72.50%(χ^(2)=7.440,P=0.006)。治疗2个周期后,2组NSE、CEA、CA19-9及CA125水平均低于治疗前,且观察组低于对照组(P<0.01);2组KPS评分及FACT-L评分均高于治疗前,且观察组高于对照组(P<0.01)。观察组与对照组不良反应总发生率比较差异无统计学意义(17.50%vs.20.00%,χ^(2)=0.082,P=0.775)。结论安罗替尼联合TC化疗方案治疗驱动基因阴性晚期肺腺癌效果较好,可有效控制疾病进展,提升患者自理能力及生存质量,且安全性良好。

Objective To analyse the clinical effect of anlotinib combined with TC chemotherapy regimen in the treatment of patients with advanced lung adenocarcinoma with negative driver gene and its influence on serum tumor marker and Karnofsky Performance Status(KPS)score.Methods Eighty patients with advanced lung adenocarcinoma with negative driver genes admitted to Hengyang Central Hospital from August 2019 to November 2020 were selected,and divided into observation group and control group with 40 patients in each group according to different treatment regimens.The control group was treated with TC chemotherapy,and the observation group was treated with anlotinib hydrochloride capsules on the basis of the treatment of the control group.The disease control rate of two groups,the levels of serum tumor markers[neuronal specific enolase(NSE),carcinoembryonic antigen(CEA),Carbohydrate antigen 19-9(CA19-9),carbohydrate antigen 125(CA125)],KPS score,Functional Assessment of Cancer Therapy-Lung(FACT-L)score before and after treatment,and the occurrence of adverse reactions were compared between the two groups.Results The disease control rate of observation group was 95.00%,which was higher than that of control group(72.50%)(χ^(2)=7.440,P=0.006).After 2 cycles of treatment,the levels of NSE,CEA,CA19-9 and CA125 in 2 groups were lower than those before treatment,and the degrees of the observation group were lower than those of the control group(P<0.01).KPS score and FACT-L score of two groups were higher than those before treatment,and the degrees of the observation group were higher than those of the control group(P<0.01).There was no significant difference in the incidence of adverse reactions between the observation group and the control group(17.50%vs.20.00%,χ^(2)=0.082,P=0.775).Conclusion Anlotinib combined with TC chemotherapy has efficacy in the treatment of patients with advanced lung adenocarcinoma with negative drive gene,which can effectively control the progression of disease,improve patients′self-care ability and quality of life,with good safety.